Online inquiry

IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15387MR)

This product GTTS-WQ15387MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ15387MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11728MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MK-0646
GTTS-WQ4980MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA C4G1
GTTS-WQ9193MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMGN853
GTTS-WQ8395MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HS006
GTTS-WQ2848MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG-570
GTTS-WQ9180MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMGN853
GTTS-WQ4806MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BT 5/9
GTTS-WQ3690MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 2287409
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW